NCCN 22nd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care™

Course description

The NCCN Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care™ attracts more than 1,500 registrants from across the United States and the globe including oncologists (in both community and academic settings), oncology fellows, nurses, pharmacists, and other health care professionals involved in the care of patients with cancer. Respected opinion leaders present the latest cancer therapies and provide updates on selected NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), the data upon which the NCCN Guidelines® are based, and quality initiatives in oncology. Topics change annually but focus on the major cancers and supportive care areas.



Target audience: 

This educational program is designed to meet the educational needs of medical, surgical, and radiation oncologists; nurses; physician assistants; pharmacists; case managers; tumor registrars; pathologists; and other health care professionals who manage patients with cancer.

Learning objectives: 

Following this program, participants should be able to:

  • Summarize key updates of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and as appropriate integrate these strategies into the management of patients with breast cancer, lung cancer, hematologic malignancies, colorectal cancer, pancreatic cancer, kidney cancer, bladder cancer, gynecologic malignancies, neuroendocrine tumors, soft tissue sarcoma, cervical/vulvar, and oropharyngeal cancers to optimize patient outcomes
  • Evaluate current therapeutic advances and emerging clinical trials data and apply relevant findings into the management of patients with cancer
  • Review issues relevant to cancer risk reduction, quality of life, and survivorship and incorporate appropriate strategies into professional practice
  • Identify opportunities for improved clinician-patient-family communication when treating patients with cancer
  • Analyze the data in clinical cancer research presented via the NCCN Foundation’s Young Investigator Awards

A detailed list of learning objectives by session topic is available here.

Event date:

03/23/2017 - 8:00am
03/25/2017 - 3:00pm
Rosen Shingle Creek
9939 Universal Blvd
Orlando, FL 32819
United States
Credits & accreditation

National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NCCN designates this live activity for a maximum of 17.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

NCCN designates this educational activity for a maximum of 17.0 contact hours.


National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

NCCN designates this knowledge-based continuing education activity for 17.0 contact hours (1.70 CEUs) of continuing education credit. UANs: 0836-0000-17-028-L01-P to 0836-0000-17-047-L01-P

Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 17.0 hours of Category I credit for completing this activity.

Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 17 CE contact hours. Activity code: C00026134; Approval Number: 170001141

Cancer Registrars
This program supports 17.0 CE hours and has been assigned the following event number: 2017-014.

Faculty & disclosure

All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

Additional information

The General Session is supported by educational grants from:

  • Ariad
  • Astellas and Medivation, Inc.
  • AstraZeneca
  • BTG International Inc.
  • Celgene Corporation
  • Celldex Therapeutics
  • Foundation Medicine
  • Genentech
  • Genomic Health, Inc.
  • Gilead Sciences, Medical Affairs
  • Lilly
  • Merrimack Pharmaceuticals, Inc.
  • Novartis
  • Pfizer
  • Prometheus Laboratories Inc.
  • Taiho Oncology
  • Takeda Oncology

This activity is supported by independent educational grants from AbbVie; Boehringer Ingelheim Pharmaceuticals, Inc.; Incyte, and Merck Co., Inc.

This activity is supported by educational funding provided by Amgen.

This educational activity is supported by a medical education grant from Exelixis, Inc.

Course summary
Available credit: 
  • 17.00 NCRA CE hours
  • 17.00 CCM clock hours
  • 17.00 ACPE contact hours
  • 17.00 ANCC contact hours
  • 17.00 AMA PRA Category 1 Credit™
  • 17.00 Participation
Course opens: 
Course expires: 
Event starts: 
03/23/2017 - 8:00am
Event ends: 
03/25/2017 - 3:00pm
Enrollments are closed.
Please login or register to take this course.